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MCKEE, Circuit Judge. 
 
 Relator-Plaintiff James Judd, M.D. appeals the District Court’s order dismissing 
the majority of his claims under the False Claims Act, 31 U.S.C. § 3729 et seq. (“FCA”), 
against Defendant Quest Diagnostics Incorporated (“Quest”) due to the public disclosure 
                                              
1 This disposition is not an opinion of the full court and pursuant to I.O.P. 5.7 does not 
constitute binding precedent. 
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bar and Rule 9(b) of the Federal Rules of Civil Procedure.  We will affirm. 
I. 
Judd is a medical doctor who has been the managing partner and chief executive 
officer of Hatboro Medical Associates, P.C., (“HMA), a Pennsylvania-based group 
medical practice, since 1988.  Quest is a large, Michigan-based diagnostic testing 
company with a number of laboratories nationwide.  In 2010, Judd filed a qui tam action 
under seal that asserted claims under the FCA, as well as multiple state and local false 
claims acts.  Quest moved to dismiss based on the public disclosure bar to FCA actions, 
31 U.S.C. § 3730(e)(4) (2006), and Rule 9(b).  In response, Judd filed an Amended 
Complaint asserting additional causes of action.   
In his Amended Complaint, Judd alleges that, in 2007, he discovered a “kickback 
scheme” that Quest had been engaging in with HMA and other healthcare providers 
throughout Southeast Pennsylvania since “sometime before 2005[.]”  (JA 59 ¶ 23.)   The 
purpose of this scheme was allegedly to induce healthcare providers to refer their patients 
to Quest in return for benefits including medical and office supplies, substance abuse and 
diagnostic laboratory testing performed by Quest at discounted rates, and free access to 
Quest’s patient database.  Judd claims that, as a result of these benefits, the providers did 
indeed refer lab work to Quest rather than other labs.  He further alleges that both Quest 
and the healthcare providers submitted to Medicaid and Medicare thousands of claims for 
reimbursement that were false because the underlying procedures were performed using 
kits, tests, and other supplies that Quest provided free of charge.  As a result of the 
alleged scheme, Judd claims that Quest violated the Anti-Kickback Statute (“AKS”), 42 
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U.S.C. § 1320a-7b, and the Stark Law, 42 U.S.C. § 1395nn, and that any claims that 
Quest submitted to Medicare and Medicaid during the period of the alleged kickback 
scheme were false and fraudulent under the FCA. 
After Judd filed his Amended Complaint, Quest again moved to dismiss based on 
Rule 9(b) and the public disclosure bar, arguing that Judd’s claims had been publicly 
disclosed in three cases:  (1) United States ex rel. Urbanek v. Laboratory Corp. of 
America Holdings, Inc., No. 00-4863 (E.D. Pa.) (“Urbanek”), filed on September 26, 
2000; (2) United States ex rel. Fair Laboratory Practices Associates v. Quest 
Diagnostics, Incorporated, No. 05-5393 (S.D.N.Y.) (“F.L.P.A.”), filed on November 18, 
2009; and (3) California ex rel. Hunter Laboratories, LLC v. Quest Diagnostics 
Incorporated, No. 34-20009-00048046 (Cal. Super. Ct.) (“Hunter Labs”), filed on 
December 14, 2009.  The District Court concluded that the public disclosure bar 
mandates dismissal of Judd’s claims regarding Quest’s scheme with providers other than 
HMA before 2010.  Judd v. Quest Diagnostics Inc., Civ. No. 10-4914 (KM), 2014 WL 
2435659 at *6-13 (D.N.J. May 30, 2014).  In so ruling, the court provided two reasons:  
First, it found that these claims had been previously publicly disclosed in Urbanek and 
Hunter Labs.  Id.  Second, it found that Judd was not an original source of the 
information on which his allegations about healthcare providers other than HMA were 
based.2  Id. at *14.  Thus, it held that it lacked jurisdiction over these claims.  Id.  In so 
                                              
2 Having dismissed Judd’s federal claims, the District Court also dismissed Judd’s state 
law claims pursuant to 28 U.S.C. § 1367.  Judd, 2014 WL 2435659 at *14, n.16.  Judd 
does not challenge that decision.  
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ruling, the District Court applied the version of the public disclosure bar in existence 
prior to the enactment of the Patient Protection and Affordable Care Act (“ACA”), Pub. 
L. 111-148, 124 Stat. 119.  Id. at *4-6.  The District Court ruled, however, that the public 
disclosure bar does not apply to Judd’s allegations regarding false claims submitted by 
HMA and the discounted testing services that Quest provided healthcare providers after 
2010 in order to induce patient referrals.  Id. at *14.  Judd voluntarily dismissed his 
claims regarding HMA.  Id. at *16.   
Agreeing with Quest’s Rule 9(b) arguments, the District Court dismissed with 
prejudice all of Judd’s claims regarding healthcare providers other than HMA, whether 
arising before or after 2010, and whether based on his free-supplies theory or his 
discounted-testing theory, because they failed to satisfy the requirements of Rule 9(b) as 
provided in United States ex rel. Foglia v. Renal Mgmt. Ventures, LLC, 754 F.3d 153 (3d 
Cir. 2014).  Judd, 2014 WL 2435659 at *14-17.  This appeal followed. 
II.  
We exercise plenary review of the District Court’s grant of the motion to dismiss 
the complaint for lack of jurisdiction due to the FCA’s public disclosure bar.  See, e.g., 
United States ex rel. Zizic v. Q2 Administrators, LLC, 728 F.3d 228, 234 (3d Cir. 2013).  
We also exercise plenary review of the District Court’s dismissal of the Amended 
Complaint for failure to state a claim.  See, e.g., United States ex rel. Foglia, 754 F.3d at 
154 n.1.  
III. 
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The FCA’s public disclosure bar “deprives courts of jurisdiction over qui tam suits 
when the relevant information has already entered the public domain through certain 
channels.”  Graham Cnty Soil & Water Conservation Dist. v. United States ex rel. 
Wilson, 559 U.S. 280, 285 (2010).  This is true both before and after the ACA amended 
the FCA.  The pre-ACA public disclosure bar mandated dismissal based on public 
disclosures at the local, state, and federal level, while the ACA-amended version requires 
dismissal only where disclosures are made in federal proceedings and sources. Compare 
31 U.S.C. § 3730(e)(4)(A) (2006) with 31 U.S.C. § 3730(e)(4)(A) (2010).  In dismissing 
Judd’s claims regarding Quest’s dealings with non-HMA healthcare providers, the 
District Court correctly held that before the FCA was amended, “the critical inquiry is 
what the law was at the time the alleged conduct in the complaint took place.”  Judd, 
2014 WL 2435659 at *6.   
As the Supreme Court noted in Hughes Aircraft Co. v. United States ex rel. 
Schumer, 520 U.S. 939, 945-46 (1997), “there is a presumption against retroactive 
legislation that is deeply rooted in our jurisprudence” that is applied “unless Congress 
had clearly manifested its intent to the contrary,” and “the legal effect of conduct should 
ordinarily be assessed under the law that existed when the conduct took place. . . .”  This 
presumption against retroactivity is even stronger where an amendment eliminates a 
defense to a qui tam suit.  Id. at 947 (Noting that amendment in question “eliminate[d] a 
defense to a qui tam suit – prior disclosure to the Government – and therefore changes the 
substance of the existing cause of action for qui tam defendants by attaching a new 
disability, in respect to transactions or considerations already past.”)   
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Here, it is clear that the public disclosure bar as amended by the ACA would 
eliminate a full defense that Quest would otherwise have to Judd’s qui tam action:  prior 
disclosure in a state court.  There is no indication, however, that Congress intended to 
make the amendments to the public disclosure bar retroactive.  See Graham, 599 U.S. at 
283 n.1 (Explaining that the ACA amendments to the public disclosure bar “make[] no 
mention of retroactivity, which would be necessary for its application to pending cases 
given that it eliminates [qui tam defendants’] claimed defense to a qui tam suit.”)  
Indeed, neither of the cases that Judd cites convinces us that the ACA-amended 
public disclosure bar must apply to qui tam claims filed after the ACA’s effective date.  
In United States ex rel. Estate of Robert Cunningham v. Millennium Laboratories of 
California, Inc., 841 F. Supp. 2d 523, 524-27 (D. Mass. 2012), aff’d in part and rev’d in 
part on other grounds, 713 F.3d 662 (1st Cir. 2013), there was no issue about which 
version of the public disclosure bar to apply because the pre-ACA public disclosure bar 
was in effect when the initial complaint was filed and when the conduct alleged in the 
complaint occurred.3  Although United States ex rel. Booker v. Pfizer, Inc., 9 F. Supp. 3d 
34 (D. Mass. 2014), does support Judd’s assertions, it is not persuasive.  In a footnote, the 
District Court there suggested that the ACA-amended public disclosure bar should apply 
despite the fact that most of the conduct at issue preceded the effective date of the ACA.  
                                              
3 In addition, although an amended complaint was filed in the case after the enactment of 
the ACA, the District Court maintained that the pre-ACA public disclosure bar was the 
appropriate version to apply because of the “well-established principle that jurisdiction is 
determined based on whether it existed at the time of the original complaint.”  
Cunningham, 841 F. Supp. 2d. at 527. 
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Id. at 44 n.3.   That court ignored the Supreme Court’s holding in Hughes Aircraft, 
however.  
 We also find no error in the District Court’s conclusion that the complaints in 
Urbanek and Hunter Labs publicly disclosed Judd’s claims regarding Quest’s dealings 
with non-HMA healthcare providers.  Judd, 2014 WL 2435659 at *7-10.  To determine 
whether the pre-ACA public disclosure bar mandates dismissal of Judd’s claims, the 
court “must first assess whether the relator’s claim is based on publicly disclosed 
allegations or transactions.”  United States ex rel. Atkinson v. Pa. Shipbuilding Co., 473 
F.3d 506, 519 (3d Cir. 2007).  “This, in turn, requires a twofold analysis.  First, [the court 
must] determine whether the information was disclosed via one of the sources listed in § 
3730(a)(4)(A).  Second, [the court must] decide whether the relator’s complaint is based 
upon those disclosures.”  Id.  The parties do not dispute that the pleadings in Urbanek and 
Hunter Labs qualify as public disclosures under the public disclosure bar in both its pre-
ACA and ACA-amended forms.   
It is clear that Judd’s principal claim that Quest distributed free supplies to 
physicians in order to induce them to refer patients to Quest for diagnostic laboratory 
testing is “based upon” the disclosures in Urbanek.  That is readily apparent from the 
District Court’s recitation of the pleadings.  Judd, 2014 WL 2435659 at *7-8.  Indeed, the 
relators in Urbanek alleged, as Judd does, that Quest violated the Anti-Kickback Act by 
providing healthcare providers with medical supplies, (compare JA 77-78 ¶ 111 with JA 
141 ¶ 30), and office supplies, (compare JA 75 ¶¶ 105-06 with JA 141 ¶ 30), in return for 
patient referrals, (compare JA 59 ¶ 25, JA ¶ 107, and JA 79 ¶ 117 with JA 141 ¶ 29, JA 
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142 ¶ 32, and JA 181 ¶ 93).  Judd’s secondary claim is that this conduct violated the FCA 
because physicians submitted fraudulent claims that included the cost of those supplies.  
(JA 84 ¶ 132.)  This claim was also made in Urbanek.  (JA 150 ¶ 72-73, JA 179 ¶ 82, and 
JA 180 ¶ 88.)  The minor variations between Judd’s Amended Complaint and the 
Urbanek pleadings do not place Judd’s claims beyond the scope of the public disclosure 
bar.  See United States ex rel. Zizic, 728 F.3d at 238 (explaining that identification of 
specific employee allegedly involved in fraud did not prevent finding that allegations 
were disclosed in prior litigation that did not name employee); United States ex rel. 
Boothe v. Sun Healthcare Grp., Inc., 496 F.3d 1169, 1174 (10th Cir. 2007) (“Not a single 
circuit has held that a complete identity of allegations, even as to time, place and manner, 
is required to implicate the public disclosure bar[.]”) (emphasis in original). 
It is also clear that the disclosures in Hunter Labs inform those in Judd’s 
Complaint regarding discounted testing services before 2010.4  Judd argues that the 
District Court erred in so finding because the allegations in Hunter Labs focused on 
Quest’s actions with respect to California and individual doctors, while his allegations 
focus on federal programs and groups of doctors.  These are distinctions without a 
difference.  The mechanism of the fraud alleged in both Hunter Labs and the instant case 
are the same:  that Quest provided discounts to medical providers in order to induce 
                                              
4 The District Court noted that the Hunter Labs case had “no effect on conduct alleged in 
[Judd’s] Amended Complaint that took place in 2010 or later relating to Quest providing 
discounted testing services, because . . . substantially similar allegations in state fora do 
not qualify as a public disclosure under the ACA-amended public disclosure bar.  See 31 
U.S.C. § 3730(e)(4)(A) (2010).”  Judd, 2014 WL 2435659 at *10 n.10.   
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referrals and that those discounts allowed the medical providers to increase profits by 
pocketing the difference between the amounts that they paid to Quest and the amounts 
they charged others, whether privately paying patients, or a state government, or the 
federal government.  As we have explained, the public disclosure bar covers actions 
“even partly based upon” previously disclosed allegations or transactions.  See United 
States ex rel. Zizic, 728 F.3d at 238.  The District Court ruling was correct. 
Because Judd’s fraud allegations regarding Quest’s alleged scheme with non-
HMA healthcare providers prior to 2010 were publicly disclosed in Urbanek and Hunter 
Labs, the District Court had jurisdiction of these claims only if Judd could show that he 
was an “original source” of his allegations.  31 U.S.C. § 3730(e)(4)(B).5  Under the pre-
ACA public disclosure bar, an “original source” is “an individual who has direct and 
independent knowledge of the information on which the allegations are based . . . .”  Id.6  
Under the “independent knowledge” prong of the original source test, “the relator must 
possess substantive information about the particular fraud, rather than merely background 
information which enables a putative relator to understand the significance of a publicly 
disclosed transaction or allegation.”  United States ex rel. Stinson, Lyons, Gerlin & 
                                              
5 As we noted above, the District Court found that Judd was an original source of his 
allegations regarding Quest’s alleged fraudulent scheme with HMA.  Judd, 2014 WL 
2435659 at *10-13.  Thus, the District Court held that “Judd may pursue his federal FCA 
claims . . . as they relate to HMA’s submissions of false claims.”  Id. at *17.  Those 
claims are not at issue, however, because Judd later dismissed them. 
 
6 The pre-ACA public disclosure bar also requires that, to be an “original source,” the 
person must have also “voluntarily provided the information to the Government before 
filing an action under this section which is based on the information.”  31 U.S.C. § 
3730(e)(4) (2006).  Quest does not challenge the District Court’s finding that Judd 
allegations on this point are adequate.  Judd, 2012 WL 2435659 at *14. 
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Bustamante, P.A. v. Prudential Ins. Co., 944 F.2d 1149, 1160 (3d Cir. 1991).  Direct 
knowledge “is based on first-hand information, and it is gained by the relator’s own 
efforts, and not by the labors of others.”  United States ex rel. Zizic, 728 F.3d at 239 
(citations and internal quotation marks omitted).  Judd bears the burden of demonstrating 
that he is an original source.  See United States ex rel. Precision Co. v. Koch Indus., Inc., 
971 F.2d 548, 551 (10th Cir. 1992).   
Although Judd argues that he had firsthand knowledge of Quest’s fraudulent 
scheme with healthcare providers other than HMA, there are no allegations in the 
Amended Complaint that support this.  On the contrary, the allegations are almost 
exclusively about dealings between HMA and Quest, and the only mention of other 
medical practices in the Amended Complaint is Judd’s allegation that “his discussions 
with other providers in South Eastern Pennsylvania . . . demonstrate that Quest’s 
practices are not limited to HMA and they extend to other medical practices.”  (JA 57 ¶ 
16.)  This bare assertion is simply not enough.  See United States ex rel. Hafter v. 
Spectrum Emergency Care, Inc., 190 F.3d 1156, 1162 (10th Cir. 1999) (“To establish 
original source status knowledge, a qui tam plaintiff must allege specific facts – as 
opposed to mere conclusions – showing exactly how and when he or she obtained direct 
and independent knowledge of the fraudulent acts alleged in the complaint.”).  Judd may 
be an original source regarding Quest’s dealings with HMA, but that does not establish 
that he is an original source regarding Quest’s dealings with other healthcare providers.  
See Rockwell Int’l Corp. v. United States, 549 U.S. 457 (2007) (Explaining that 
“3730(e)(4) does not permit such claim smuggling,” because a relator’s “decision to join 
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all of his or her claims in a single lawsuit should not rescue claims that would have been 
doomed by section (e)(4) if they had been asserted in a separate action.”)7 
IV. 
After resolving issues involving the public disclosure bar, the District Court 
dismissed with prejudice all of Judd’s claims regarding healthcare providers other than 
HMA, whether arising before or after the enactment of the ACA, and whether based on 
his free-supplies theory or his discounted-testing theory, because they failed to satisfy the 
                                              
7   Judd also contends that he is an “original source” under the ACA-amended public 
disclosure bar.  The relevant portion of the ACA-amended “original source” doctrine 
provides:  “[O]riginal source means an individual who . . . has knowledge that is 
independent of and materially adds to the publicly disclosed allegations or transactions.”  
31 U.S.C. § 3730(e)(4)(B)(2) (2010).  As discussed above, Judd has not shown that his 
allegations are “independent of” the public disclosures in Urbanek.  Judd does not 
address this, however, and focuses instead on the “materially adds to” element.  To date, 
only the Eighth Circuit has addressed the meaning of the phrase.  In United States ex rel. 
Paulos v. Stryker Corp., 762 F.3d 688, 694-96 (8th Cir. 2014), relying on the dictionary 
definitions of “add” and “materially,” the Eighth Circuit opined that a relator fails to 
qualify as an original source if he fails to show that “his knowledge (even if gained early 
and independently) materially contributes anything of import to the public knowledge 
about the alleged fraud.”  Id. at 694-95. 
 
Repackaging the argument he made regarding the applicability of Urbanek, Judd 
contends that the fraud he alleges “materially adds to” the publicly disclosed allegations 
in Urbanek because it occurred during an entirely different timeframe.  In so arguing, 
Judd relies again on United States ex rel. Booker v. Pfizer, 9 F. Supp. 3d 34 (D. Mass. 
2014) as he did in his arguments regarding which version of the public disclosure bar to 
apply.  In that case, the actions alleged to implicate the public disclosure bar disclosed 
conduct in the years prior to 2008.  Id. at 44.  In contrast, the “central allegation” of the 
relators’ action was that Pfizer’s conduct continued after August 2009.  Id.  The District 
Court opined that, by virtue of the difference in timeframe, the relators’ allegations 
“materially added” to prior disclosures and described a “‘new’ fraud.”  Id. at 46-47 & n.4.  
For the reasons discussed above, the few medical supplies included in Judd’s allegations 
that were not mentioned in Urbanek and his alleged different timeframe do not establish a 
“new fraud” of the type alleged in Booker.  Judd is not an “original source” for the 
purposes of the ACA-amended public disclosure bar. 
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requirements of Rule 9(b) of the Federal Rules of Civil Procedure.  Id. at *14-17.  We 
agree. 
Rule 9(b) provides, in relevant part, that “[i]n alleging fraud or mistake, a party 
must state with particularity the circumstances constituting fraud or mistake.”  Fed. R. 
Civ. P. 9(b).  Thus, a plaintiff must allege “the who, what, when, where and how of the 
events at issue.”  In re Rockefeller Ctr. Props., Inc. Secs. Litig., 311 F.3d 198, 217 (3d 
Cir. 2002) (citation and internal quotation marks omitted).   When the District Court 
rendered its decision, we had not yet specifically determined what Rule 9(b) requires of a 
FCA claimant.  One week later, however, we resolved this issue in United States ex rel. 
Foglia v. Renal Ventures Mgmt., LLC, 754 F.3d 153 (3d Cir. 2014).  There, we adopted 
the approach of the First, Fifth, and Ninth Circuits, which “have taken a more nuanced 
reading of the heightened pleading requirements of Rule 9(b), holding that it is sufficient 
for a plaintiff to allege ‘particular details of a scheme to submit false claims paired with 
reliable indicia that lead to a strong inference that claims were actually submitted.’”  Id. 
at 156 (quotation and citation omitted).   
Despite this more lenient standard, Judd’s allegations fail.  He provides no reason 
to believe that Quest submitted claims for Medicare reimbursement in connection with its 
kickbacks.  Additionally, the paragraphs of his Amended Complaint that he argues 
contain specific allegations have nothing to do with Quest’s dealings with non-HMA 
medical providers.  (See JA 81 ¶ 126, JA 83 ¶ 129, and JA 84 ¶ 131.)  The only mention 
he makes of other providers is a brief, conclusory assertion that “his discussions with 
other providers in South Eastern Pennsylvania . . . demonstrate that Quest’s practices are 
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not limited to HMA and they extend to other medical practices.”  (JA 57 ¶ 16.)  As we 
explained in Foglia, “describing a mere opportunity for fraud will not suffice.”  Id. at 
158; see also United States ex rel. Nunnally v. West Calcasieu Cameron Hospital, 519 F. 
App’x 890, 894 (5th Cir. 2013) (finding the relator’s allegations deficient under Rule 9(b) 
because he failed to allege, inter alia, “the identity of any physicians, actual inducements, 
or improper referrals.”); United States ex rel. Cafasso v. Gen. Dynamics C4 Sys., Inc., 
637 F.3d 1047, 1057 (9th Cir. 2011) (Explaining that a relator must do more than 
“identif[y] a general sort of fraudulent conduct [while] specif[ying] no particular 
circumstances of any discrete fraudulent statement.”); Ebeid ex rel. United States v. 
Lungwitz, 616 F.3d 993, 1000 (9th Cir. 2010) (finding the relator’s complaint deficient 
because it “lack[ed] any details or facts setting out the who, what, when, where and how 
of the financial relationship or alleged referrals.”) (citation and internal quotation marks 
omitted). 
IV. 
For the reasons set forth above, we will affirm the judgment of the District Court. 
 
 
